“The fourth quarter of 2023 continued to be positive and eventful for
Martin Jönsson, CEO
Financial information for October – December, 2023
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled
SEK 0 thousand (0). - Earnings for the period totaled
SEK -9,756 thousand (-10,948). - Earnings per share, basic, totaled
SEK -0.16 (-0.22). - Cash flow from operating activities totaled
SEK -8,361 thousand (-51,194). - Total assets at the end of the period amounted to
SEK 32,001 thousand (70,836). - Cash and cash equivalents at the end of the period totaled
SEK 29,100 thousand (25,577).
Financial information for January – December, 2023
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled
SEK 0 thousand (0). - Earnings for the period totaled
SEK -37,167 thousand (-56,239). - Earnings per share, basic, totaled
SEK -0.60 (-1.18). - Cash flow from operating activities totaled
SEK 3,057 thousand (-99,911). - Total assets at the end of the period amounted to
SEK 32,001 thousand (70,836). - Cash and cash equivalents at the end of the period totaled
SEK 29,100 thousand (25,577).
Significant events during the period October – December, 2023
- The company reports in early October that
Japan has granted a patent for NeuroRestore ACD856. - In October, the company publishes a new article about the target mechanism behind Alzstatin, which is being developed for the treatment of Alzheimer’s disease.
Significant events during the period January – September, 2023
- In January, the company selects a candidate drug (CD) and initiates the preclinical development phase with the company’s preventive and disease-modifying drug candidate Alzstatin ACD680.
- In January, the last patient is included in the Phase II clinical trial with the leading non-opioid drug candidate in the Painless platform, ACD440, which is being developed to treat peripheral neuropathic pain.
- The company announces on
March 13 that the last patient has completed treatment in the above clinical trial with ACD440. - In April, the company has an abstract on non-opioid ACD440 for neuropathic pain accepted at the EFIC 2023 Conference.
- On
May 17 , the company holds its Annual General Meeting and Dr Janet Hoogstraate is elected to serve as a new member of the Board of Directors. - The company announces on
May 22 that a European patent has been granted for the NeuroRestore ACD856 Alzheimer’s project. - On
May 24 the company announces positive proof-of-mechanism (PoM) data from the Phase IIa clinical trial in neuropathic pain with the non-opioid ACD440. - On
July 3 , the company publishes a new scientific article presenting preclinical results demonstrating the antidepressant effects of NeuroRestore ACD856. - On
July 11 , the company publishes new disease-modifying data regarding NeuroRestore ACD856 for the treatment of Alzheimer’s and cognitive disorders. - On
August 9 , the company publishes favorable clinical results from the Phase I clinical trial with NeuroRestore ACD856 for the treatment of Alzheimer’s. - On
September 20 , the company presents positive Phase II clinical data on ACD440 for neuropathic pain at the 2023European Pain Federation (EFIC) conference.
Significant events after the end of the period
- On
January 29 , the company selects a drug candidate and enter the next phase of development with TrkA-NAM ACD137 for the treatment of osteoarthritis pain and other severe pain conditions.
The full report is attached as PDF and is available on the company’s website: www.alzecurepharma.com/en/section/investors/financial-reports/
© Modular Finance, source